ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1925

TGFβ Promotes Fibrosis By MYST1-Dependent Epigenetic Regulation of Autophagy

Ariella Zehender1, Neng-Yu Lin2, Adrian Stefanica3, Chih-Wei Chen4, Alina Soare5, Thomas Wohlfahrt6, Simon Rauber6, Christina Bergmann7, Andreas Ramming8, Oliver Distler9, Georg Schett10 and Jörg Distler5, 11Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 2Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 31Department of Internal Medicine 3 – Rheumatology and Immunology, University of Erlangen, Erlangen, Germany, 4Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 5Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 6Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 7Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 8Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 9Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 10Department of Internal Medicine 3 – Rheumatology and Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autophagy, Epigenetics, fibrosis, systemic sclerosis and transforming growth factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Autophagy (Atg) is catabolic process allowing cells to degrade unnecessary or dysfunctional cellular organelles. Aberrant activation of Atg has been implicated into the pathogenesis of various diseases.

Methods:

We generated Atg7fl/flx Col1a2;CreER mice with selective inactivation of Atg in fibroblasts. The role of the Atg was investigated in the model of bleomycin- and TβRIact-induced dermal and pulmonary fibrosis. Overexpression of Myst1 and Beclin1 was achieved by adenoviral overexpression. ChIP and reporter assays were performed to study physical and functional interactions between MYST1 and SMAD3.

Results:

Atg is strongly activated in fibroblasts from SSc skin and also in experimental dermal and pulmonary fibrosis as compared to respective non-fibrotic control tissue with overexpression of ATG7 and of BECLIN, downregulation of the autophagy substrate p62 and activation of autophagy-dependent reporter activity. The aberrant activation of Atg has profound stimulatory effects on fibroblasts. Activation of Atg by forced expression of BECLIN1 promoted fibroblast-to-myofibroblast transition and stimulates the collagen release in vitro and in vivo. Moreover, inactivation of autophagy by fibroblast-specific knockout of Atg7prevented myofibroblast differentiation and ameliorated fibrosis, demonstrating that activation of Atg is both, sufficient and required, for fibroblast activation and tissue fibrosis. We also provide evidence that TGFβ activates Atg by an epigenetic mechanism to amplify its profibrotic effects. TGFβ induces Atg in fibrotic diseases by SMAD3-dependent downregulation of the H4K16-histoneacetlytransferase MYST1, which controls the expression of core components of the Atg machinery such as ATG7 and BECLIN1. Forced expression of MYST1 abrogates the stimulatory effects of TGFβ on Atg and re-establishes the epigenetic control of autophagy in fibrotic conditions. Overexpression of MYST1 prevents the aberrant activation of Atg, inhibits TGFβ-induced fibroblast activation and ameliorates experimental dermal and pulmonary fibrosis.

Conclusion:

We demonstrate that the epigenetic control of Atg is disturbed by a TGFβ-dependent downregulation of MYST1 in SSc. The resulting uncontrolled activation of Atg promotes fibroblast-to-myofibroblast transition and tissue fibrosis. Restoration of the epigenetic control of autophagy limits the profibrotic effects of TGFβ and ameliorates experimental fibrosis. These findings link uncontrolled TGFβ signaling to aberrant autophagy and altered epigenetics in fibrotic diseases.


Disclosure: A. Zehender, None; N. Y. Lin, None; A. Stefanica, None; C. W. Chen, None; A. Soare, None; T. Wohlfahrt, None; S. Rauber, None; C. Bergmann, None; A. Ramming, None; O. Distler, 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemomAb, EpiPharm, Ergonex, espeRare foundation, GSK,Roche-Genentech, Inventiva, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Seroda, 2; G. Schett, None; J. Distler, 4D Science, 1,Anamar Medical, Active Biotech, Array Biopma, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, GSK, Novartis, Sanofi-Aventis, UCB, 2,Actelion Pharmaceuticals US, Active Biotech, Anamar, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi, UCB, 5.

To cite this abstract in AMA style:

Zehender A, Lin NY, Stefanica A, Chen CW, Soare A, Wohlfahrt T, Rauber S, Bergmann C, Ramming A, Distler O, Schett G, Distler J. TGFβ Promotes Fibrosis By MYST1-Dependent Epigenetic Regulation of Autophagy [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tgf%ce%b2-promotes-fibrosis-by-myst1-dependent-epigenetic-regulation-of-autophagy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tgf%ce%b2-promotes-fibrosis-by-myst1-dependent-epigenetic-regulation-of-autophagy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology